157 related articles for article (PubMed ID: 16429271)
1. Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent.
Ni Y; Chen F; Mulier S; Sun X; Yu J; Landuyt W; Marchal G; Verbruggen A
Eur Radiol; 2006 May; 16(5):1031-40. PubMed ID: 16429271
[TBL] [Abstract][Full Text] [Related]
2. Conspicuity of zones of ablation after radiofrequency ablation in porcine livers: comparison of an extracellular and an SPIO contrast agent.
Bangard C; Stippel DL; Berg F; Kasper HU; Hellmich M; Fischer JH; Hölscher A; Lackner K; Gossmann A
J Magn Reson Imaging; 2008 Jul; 28(1):263-70. PubMed ID: 18581392
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance-based visualization of thermal ablative margins around hepatic tumors by means of systemic ferucarbotran administration before radiofrequency ablation: animal study to reveal the connection between excess iron deposition and T2*-weighted hypointensity in ablative margins.
Nagai M; Yamaguchi M; Mori K; Furuta T; Ashino H; Kurosawa H; Kasahara H; Minami M; Fujii H
Invest Radiol; 2015 Jun; 50(6):376-83. PubMed ID: 25695671
[TBL] [Abstract][Full Text] [Related]
4. Radiofrequency ablated lesion in the normal porcine lung: long-term follow-up with MRI and pathology.
Oyama Y; Nakamura K; Matsuoka T; Toyoshima M; Yamamoto A; Okuma T; Ikura Y; Ueda M; Inoue Y
Cardiovasc Intervent Radiol; 2005; 28(3):346-53. PubMed ID: 15886942
[TBL] [Abstract][Full Text] [Related]
5. Early assessment of coagulation necrosis after hepatic microwave ablation: a comparison of non-enhanced and enhanced T1-weighted images.
Jia ZY; Chen QF; Yang ZQ; Wu WT; Shi HB; Liu S
Abdom Radiol (NY); 2017 Jun; 42(6):1781-1787. PubMed ID: 28180923
[TBL] [Abstract][Full Text] [Related]
6. Unenhanced magnetic resonance imaging immediately after radiofrequency ablation of liver malignancy: preliminary results.
D'Onofrio M; Cardobi N; Ruzzenente A; Conci S; Ciaravino V; Guglielmi A; Mucelli RP
Abdom Radiol (NY); 2018 Jun; 43(6):1379-1385. PubMed ID: 28861631
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging characteristics of renal tumors after radiofrequency ablation.
Svatek RS; Sims R; Anderson JK; Abdel-Aziz K; Cadeddu JA
Urology; 2006 Mar; 67(3):508-12. PubMed ID: 16504265
[TBL] [Abstract][Full Text] [Related]
8. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
[TBL] [Abstract][Full Text] [Related]
9. Comparison between nonspecific and necrosis-avid gadolinium contrast agents in vascular disrupting agent-induced necrosis of rodent tumors at 3.0T.
Wang H; Miranda Cona M; Chen F; Li J; Yu J; Feng Y; Peeters R; De Keyzer F; Marchal G; Ni Y
Invest Radiol; 2011 Sep; 46(9):531-8. PubMed ID: 21577133
[TBL] [Abstract][Full Text] [Related]
10. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
11. Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model.
Van de Putte M; Wang H; Chen F; De Witte PA; Ni Y
Oncol Rep; 2008 Apr; 19(4):927-32. PubMed ID: 18357377
[TBL] [Abstract][Full Text] [Related]
12. Visualization and temporal/spatial characterization of cardiac radiofrequency ablation lesions using magnetic resonance imaging.
Lardo AC; McVeigh ER; Jumrussirikul P; Berger RD; Calkins H; Lima J; Halperin HR
Circulation; 2000 Aug; 102(6):698-705. PubMed ID: 10931812
[TBL] [Abstract][Full Text] [Related]
13. Radiofrequency ablation of liver malignancies: MRI for evaluation of response.
Aliberti C; Soriani M; Tilli M; Benea G; De Giorgi U; Fiorentini G
J Chemother; 2004 Nov; 16 Suppl 5():79-81. PubMed ID: 15675486
[TBL] [Abstract][Full Text] [Related]
14. Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma.
Iwamoto T; Imai Y; Igura T; Kogita S; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Ohashi H; Fujita N; Kudo M; Takehara T
Dig Dis; 2017; 35(6):574-582. PubMed ID: 29040990
[TBL] [Abstract][Full Text] [Related]
15. Radiofrequency ablation of liver VX2 tumor: experimental results with MR diffusion-weighted imaging at 3.0T.
Liu Y; Lu L; Jin H; Chen X; Zhang Z; Liu Z; Liang C
PLoS One; 2014; 9(8):e104239. PubMed ID: 25102074
[TBL] [Abstract][Full Text] [Related]
16. Rhein-based necrosis-avid MRI contrast agents for early evaluation of tumor response to microwave ablation therapy.
Wu T; Zhang J; Jin Q; Gao M; Zhang D; Zhang L; Feng Y; Ni Y; Yin Z
Magn Reson Med; 2019 Dec; 82(6):2212-2224. PubMed ID: 31418484
[TBL] [Abstract][Full Text] [Related]
17. Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid for Quantitative Assessment of Vascular Effects on Hepatocellular-Carcinoma Lesions Treated by Transarterial Chemoembolization or Radiofrequency Ablation.
Ippolito D; Trattenero C; Talei Franzesi C; Casiraghi A; Lombardi S; Vacirca F; Corso R; Sironi S
J Comput Assist Tomogr; 2016; 40(5):692-700. PubMed ID: 27560010
[TBL] [Abstract][Full Text] [Related]
18. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation.
Lee DH; Lee JM; Lee JY; Kim SH; Kim JH; Yoon JH; Kim YJ; Lee JH; Yu SJ; Han JK; Choi BI
J Hepatol; 2015 May; 62(5):1122-30. PubMed ID: 25529623
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma.
Kang TW; Rhim H; Lee J; Song KD; Lee MW; Kim YS; Lim HK; Jang KM; Kim SH; Gwak GY; Jung SH
Eur Radiol; 2016 Oct; 26(10):3437-46. PubMed ID: 26747262
[TBL] [Abstract][Full Text] [Related]
20. Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging.
Ni Y; Pislaru C; Bosmans H; Pislaru S; Miao Y; Bogaert J; Dymarkowski S; Yu J; Semmler W; Van de Werf F; Baert AL; Marchal G
Eur Radiol; 2001; 11(5):876-83. PubMed ID: 11372627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
